$ABUS
Arbutus Biopharma Corp Stock $abus

$abus Overview Financials Valuation SEC Filings Company Website

2019 Q1 Form 10-Q Financial Statement

#000144702819000015 Filed on May 06, 2019

Income Statement

Concept	2019 Q1	2018 Q1
Revenue	$679.0K	$1.436M
YoY Change	-52.72%	511.06%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.410M	$3.670M
YoY Change	20.16%	-15.24%
% of Gross Profit
Research & Development	$14.71M	$13.95M
YoY Change	5.47%	0.56%
% of Gross Profit
Depreciation & Amortization	$509.0K	$602.0K
YoY Change	-15.45%	80.24%
% of Gross Profit
Operating Expenses	$19.88M	$19.84M
YoY Change	0.17%	7.05%
Operating Profit	-$19.20M	-$18.41M
YoY Change	4.3%	0.58%
Interest Expense	$12.00K	$104.0K
YoY Change	-88.46%	147.62%
% of Operating Profit
Other Income/Expense, Net	-$4.055M	$976.0K
YoY Change	-515.47%	-397.56%
Pretax Income	-$23.25M	-$17.43M
YoY Change	33.4%	-6.44%
Income Tax	$0.00
% Of Pretax Income
Net Earnings	-$23.25M	-$17.43M
YoY Change	33.4%	-6.43%
Net Earnings / Revenue	-3424.3%	-1213.72%
Basic Earnings Per Share	-$0.47	-$0.36
Diluted Earnings Per Share	-$417.1K	-$0.36
COMMON SHARES
Basic Shares Outstanding	56.12M shares	55.07M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q1	2018 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$110.6M	$172.5M
YoY Change	-35.88%	56.25%
Cash & Equivalents	$83.97M	$12.46M
Short-Term Investments	$26.60M	$160.1M
Other Short-Term Assets	$700.0K	$1.500M
YoY Change	-53.33%	-6.25%
Inventory
Prepaid Expenses
Receivables	$923.0K	$719.0K
Other Receivables	$300.0K	$400.0K
Total Short-Term Assets	$112.5M	$175.2M
YoY Change	-35.79%	45.66%
LONG-TERM ASSETS
Property, Plant & Equipment	$9.667M	$11.83M
YoY Change	-18.28%	3.2%
Goodwill	$22.47M	$24.36M
YoY Change	-7.77%	0.0%
Intangibles	$43.84M	$58.65M
YoY Change	-25.25%	-41.03%
Long-Term Investments	$17.68M
YoY Change
Other Assets		$0.00
YoY Change		-100.0%
Total Long-Term Assets	$96.73M	$94.84M
YoY Change	1.99%	-35.86%
TOTAL ASSETS
Total Short-Term Assets	$112.5M	$175.2M
Total Long-Term Assets	$96.73M	$94.84M
Total Assets	$209.2M	$270.0M
YoY Change	-22.52%	0.7%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.300M	$900.0K
YoY Change	155.56%	-43.75%
Accrued Expenses	$6.100M	$6.400M
YoY Change	-4.69%	20.75%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$8.823M	$10.40M
YoY Change	-15.13%	-4.37%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change		-100.0%
Other Long-Term Liabilities	$6.500M	$10.30M
YoY Change	-36.89%	-30.87%
Total Long-Term Liabilities	$6.500M	$10.30M
YoY Change	-36.89%	-61.71%
TOTAL LIABILITIES
Total Short-Term Liabilities	$8.823M	$10.40M
Total Long-Term Liabilities	$6.500M	$10.30M
Total Liabilities	$28.01M	$37.61M
YoY Change	-25.53%	-52.42%
SHAREHOLDERS EQUITY
Retained Earnings	-$831.2M	-$757.8M
YoY Change	9.68%	13.15%
Common Stock	$882.1M	$876.3M
YoY Change	0.67%	0.62%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$181.2M	$232.4M
YoY Change
Total Liabilities & Shareholders Equity	$209.2M	$270.0M
YoY Change	-22.52%	0.7%

Cashflow Statement

Concept	2019 Q1	2018 Q1
OPERATING ACTIVITIES
Net Income	-$23.25M	-$17.43M
YoY Change	33.4%	-6.43%
Depreciation, Depletion And Amortization	$509.0K	$602.0K
YoY Change	-15.45%	80.24%
Cash From Operating Activities	-$16.58M	-$19.97M
YoY Change	-16.96%	13.87%
INVESTING ACTIVITIES
Capital Expenditures	$31.00K	$248.0K
YoY Change	-87.5%	-92.75%
Acquisitions
YoY Change
Other Investing Activities	$61.06M	-$75.42M
YoY Change	-180.96%	-383.32%
Cash From Investing Activities	$61.03M	-$75.67M
YoY Change	-180.66%	-426.22%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$2.248M	$66.27M
YoY Change	-96.61%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$2.536M	$54.37M
YoY Change	-95.34%	15257.91%
NET CHANGE
Cash From Operating Activities	-$16.58M	-$19.97M
Cash From Investing Activities	$61.03M	-$75.67M
Cash From Financing Activities	$2.536M	$54.37M
Net Change In Cash	$47.03M	-$41.83M
YoY Change	-212.42%	-795.56%
FREE CASH FLOW
Cash From Operating Activities	-$16.58M	-$19.97M
Capital Expenditures	$31.00K	$248.0K
Free Cash Flow	-$16.61M	-$20.22M
YoY Change	-17.83%	-3.55%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2019Q1	dei	Amendment Flag AmendmentFlag	false
CY2019Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	600000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	5296000	USD
CY2019Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2018Q4	abus	Accrued Payroll Current AccruedPayrollCurrent	2341000	USD
CY2019Q1	abus	Accrued Payroll Current AccruedPayrollCurrent	773000	USD
CY2018Q4	abus	Accrued Research And Development AccruedResearchAndDevelopment	2716000	USD
CY2019Q1	abus	Accrued Research And Development AccruedResearchAndDevelopment	3220000	USD
CY2018Q1	abus	Adjustmentsto Additional Paidin Capital Certain Fair Value Adjustmentsto Liability Stock Option Awards AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards	-504000	USD
CY2019Q1	abus	Adjustmentsto Additional Paidin Capital Certain Fair Value Adjustmentsto Liability Stock Option Awards AdjustmentstoAdditionalPaidinCapitalCertainFairValueAdjustmentstoLiabilityStockOptionAwards	47000	USD
	abus	Cumulative Contributionfor Product CumulativeContributionforProduct	3668000	CAD
	abus	Cumulative Contributionfor Product CumulativeContributionforProduct	2773000	USD
CY2018Q4	abus	Employee Stock Options Liability Classified Outstanding EmployeeStockOptionsLiabilityClassifiedOutstanding	479000	USD
CY2019Q1	abus	Employee Stock Options Liability Classified Outstanding EmployeeStockOptionsLiabilityClassifiedOutstanding	414000	USD
CY2019Q1	abus	Fixed Lease Cost FixedLeaseCost	300000	USD
CY2018Q1	abus	Increase Decrease In Fair Value Of Contingent Consideration Liability IncreaseDecreaseInFairValueOfContingentConsiderationLiability	-848000	USD
CY2019Q1	abus	Increase Decrease In Fair Value Of Contingent Consideration Liability IncreaseDecreaseInFairValueOfContingentConsiderationLiability	125000	USD
CY2019Q1	abus	Lessee Operating Lease Numberof Leases LesseeOperatingLeaseNumberofLeases	3	lease
	abus	Maximum Contribution For Product MaximumContributionForProduct	7179000	USD
CY2019Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2019Q1	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	0	USD
	abus	Maximum Contribution For Product MaximumContributionForProduct	9256000	CAD
	abus	Percent Of Costs Funded By Tpc PercentOfCostsFundedByTPC	0.27
CY2019Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
CY2019Q1	dei	Document Period End Date DocumentPeriodEndDate	2019-03-31
CY2019Q1	dei	Document Type DocumentType	10-Q
CY2019Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001447028
CY2019Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	56850172	shares
CY2019Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2019Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2019Q1	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2019Q1	dei	Entity Registrant Name EntityRegistrantName	Arbutus Biopharma Corp
CY2019Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2018Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	9429000	USD
CY2019Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	6828000	USD
CY2018Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	3192000	USD
CY2019Q1	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	2344000	USD
CY2019Q1	abus	Royalty Guarantees Commitments Percentage RoyaltyGuaranteesCommitmentsPercentage	0.025
CY2019Q1	abus	Strightline Fixed Lease Cost StrightlineFixedLeaseCost	300000	USD
CY2019Q1	abus	Wholly Owned Subsidiaries Includedin Financial Statements WhollyOwnedSubsidiariesIncludedinFinancialStatements	2	subsidiary
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1431000	USD
CY2019Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	923000	USD
CY2018Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	871000	USD
CY2019Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	491000	USD
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6896000	USD
CY2019Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7405000	USD
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-48170000	USD
CY2019Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-48192000	USD
CY2018Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	48084000	USD
CY2019Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	49594000	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1510000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1665000	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	135000	USD
CY2018Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	22095109	shares
CY2019Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	26029535	shares
CY2018Q4	us-gaap	Assets Assets	227905000	USD
CY2019Q1	us-gaap	Assets Assets	209216000	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	129229000	USD
CY2019Q1	us-gaap	Assets Current AssetsCurrent	112486000	USD
CY2018Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	-848000	USD
CY2019Q1	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	125000	USD
CY2017Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	10424000	USD
CY2018Q1	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	9576000	USD
CY2018Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	3126000	USD
CY2019Q1	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	3251000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	36942000	USD
CY2019Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	83969000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	54292000	USD
CY2018Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	12461000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	36942000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	83969000	USD
CY2018Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-41831000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	47027000	USD
CY2018Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue
CY2019Q1	us-gaap	Common Stock No Par Value CommonStockNoParValue
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	55518800	shares
CY2019Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	56255816	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	55518800	shares
CY2019Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	56255816	shares
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	879405000	USD
CY2019Q1	us-gaap	Common Stock Value CommonStockValue	882143000	USD
CY2018Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-17429000	USD
CY2019Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-23273000	USD
CY2018Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	12661000	USD
CY2018Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.36
CY2019Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.47
CY2018Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3669000	USD
CY2019Q1	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	12661000	USD
CY2018Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	645000	USD
CY2018Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-565000	USD
CY2019Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	38000	USD
CY2018Q4	us-gaap	Equity Method Investments EquityMethodInvestments	22224000	USD
CY2019Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4412000	USD
CY2019Q1	us-gaap	Equity Method Investments EquityMethodInvestments	17675000	USD
CY2018Q4	us-gaap	Goodwill Goodwill	22471000	USD
CY2019Q1	us-gaap	Goodwill Goodwill	22471000	USD
CY2018Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-526000	USD
CY2019Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	8000	USD
CY2018Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	0	USD
CY2019Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-4651000	USD
CY2018Q1	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-565000	USD
CY2019Q1	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	38000	USD
CY2018Q1	us-gaap	Gain Loss On Sale Of Equity Investments GainLossOnSaleOfEquityInvestments	0	USD
CY2019Q1	us-gaap	Gain Loss On Sale Of Equity Investments GainLossOnSaleOfEquityInvestments	-4651000	USD
CY2018Q1	us-gaap	Depreciation Depreciation	602000	USD
CY2019Q1	us-gaap	Depreciation Depreciation	509000	USD
CY2018Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	602000	USD
CY2019Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	509000	USD
CY2018Q1	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	2336000	USD
CY2019Q1	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	2715000	USD
CY2018Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2019Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	9000	USD
CY2018Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	389000	USD
CY2019Q1	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	291000	USD
CY2018Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-4187000	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-2746000	USD
CY2018Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	317000	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-508000	USD
CY2018Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-1022000	USD
CY2019Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0	USD
CY2018Q1	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	2000	USD
CY2019Q1	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-98000	USD
CY2018Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	0	USD
CY2019Q1	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-167000	USD
CY2018Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	0	USD
CY2019Q1	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-87000	USD
CY2018Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-687000	USD
CY2019Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2110000	USD
CY2018Q1	us-gaap	Increase Decrease In Restructuring Reserve IncreaseDecreaseInRestructuringReserve	1029000	USD
CY2019Q1	us-gaap	Increase Decrease In Restructuring Reserve IncreaseDecreaseInRestructuringReserve	-139000	USD
CY2018Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	43836000	USD
CY2019Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	43836000	USD
CY2018Q1	us-gaap	Interest Expense InterestExpense	104000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	2038000	USD
CY2019Q1	us-gaap	Interest Expense InterestExpense	12000	USD
CY2018Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	758000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	598000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	581000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1425000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	677000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	657000	USD
CY2019Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	745000	USD
CY2018Q4	us-gaap	Liabilities Liabilities	27671000	USD
CY2019Q1	us-gaap	Liabilities Liabilities	28007000	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	227905000	USD
CY2019Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	209216000	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11239000	USD
CY2019Q1	us-gaap	Liabilities Current LiabilitiesCurrent	8823000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	54367000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2536000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-75666000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	61033000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-19967000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16580000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-17429000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-23251000	USD
CY2018Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-19765000	USD
CY2019Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-25966000	USD
CY2018Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	976000	USD
CY2019Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4180000	USD
CY2018Q1	us-gaap	Operating Expenses OperatingExpenses	19841000	USD
CY2019Q1	us-gaap	Operating Expenses OperatingExpenses	19750000	USD
CY2018Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-18405000	USD
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-19071000	USD
CY2019Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	400000	USD
CY2019Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	3871000	USD
CY2018Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	0	USD
CY2019Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	599000	USD
CY2018Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	USD
CY2019Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3272000	USD
CY2019Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4100000	USD
CY2018Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	0	USD
CY2019Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	312000	USD
CY2018Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	0	USD
CY2019Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3081000	USD
CY2019Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3200000	USD
CY2019Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.087
CY2019Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y2M12D
CY2018Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	309000	USD
CY2019Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	0	USD
CY2018Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	0	USD
CY2019Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-22000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-22000	USD
CY2018Q1	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	75418000	USD
CY2019Q1	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	0	USD
CY2019Q1	us-gaap	Payments For Restructuring PaymentsForRestructuring	466000	USD
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2792000	USD
CY2019Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	682000	USD
CY2018Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	248000	USD
CY2019Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1164000	shares
CY2018Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	1164000	shares
CY2019Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	1164000	shares
CY2018Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	66265000	USD
CY2019Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2248000	USD
CY2019Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	31000	USD
CY2018Q1	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	2336000	USD
CY2019Q1	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	2715000	USD
CY2018Q4	us-gaap	Preferred Stock Including Additional Paid In Capital Net Of Discount PreferredStockIncludingAdditionalPaidInCapitalNetOfDiscount	126136000	USD
CY2019Q1	us-gaap	Preferred Stock Including Additional Paid In Capital Net Of Discount PreferredStockIncludingAdditionalPaidInCapitalNetOfDiscount	128851000	USD
CY2018Q4	us-gaap	Preferred Stock No Par Value PreferredStockNoParValue
CY2019Q1	us-gaap	Preferred Stock No Par Value PreferredStockNoParValue
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1164000	shares
CY2018Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	1164000	shares
CY2019Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	1164000	shares
CY2018Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
CY2019Q1	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	9000	USD
CY2018Q1	us-gaap	Proceeds From Sale Of Restricted Investments ProceedsFromSaleOfRestrictedInvestments	0	USD
CY2019Q1	us-gaap	Proceeds From Sale Of Restricted Investments ProceedsFromSaleOfRestrictedInvestments	61055000	USD
CY2018Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	103000	USD
CY2019Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	288000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	10145000	USD
CY2019Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9667000	USD
CY2018Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	12001000	USD
CY2019Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
CY2018Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13949000	USD
CY2019Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	14712000	USD
	us-gaap	Restructuring Charges RestructuringCharges	4900000	USD
CY2018Q1	us-gaap	Restructuring Charges RestructuringCharges	1621000	USD
CY2019Q1	us-gaap	Restructuring Charges RestructuringCharges	117000	USD
CY2018Q4	us-gaap	Restructuring Reserve RestructuringReserve	1331000	USD
CY2019Q1	us-gaap	Restructuring Reserve RestructuringReserve	982000	USD
CY2018Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	1331000	USD
CY2019Q1	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	982000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-805221000	USD
CY2019Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-831187000	USD
CY2018Q1	us-gaap	Revenues Revenues	1436000	USD
CY2019Q1	us-gaap	Revenues Revenues	679000	USD
CY2018Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0	USD
CY2019Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	3248000	USD
CY2018Q1	us-gaap	Share Based Compensation ShareBasedCompensation	955000	USD
CY2019Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1522000	USD
CY2018Q4	us-gaap	Short Term Investments ShortTermInvestments	87675000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	200234000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	181209000	USD
CY2018Q1	us-gaap	Sublease Income SubleaseIncome	0	USD
CY2019Q1	us-gaap	Sublease Income SubleaseIncome	100000	USD
CY2019Q1	us-gaap	Variable Lease Cost VariableLeaseCost	100000	USD
CY2018Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	55071964	shares
CY2019Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	55740121	shares
CY2019Q1	us-gaap	Short Term Investments ShortTermInvestments	26621000	USD
CY2018Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	66265000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2248000	USD
CY2018Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	103000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	288000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	182473000	USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	232418000	USD
CY2019Q1	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nature of business and future operations</font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Arbutus Biopharma Corporation (the “Company” or “Arbutus”) is a biopharmaceutical business dedicated to discovering, developing, and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by the hepatitis B virus (“HBV”). To pursue its strategy of developing a curative combination regimen, the Company has assembled a pipeline of multiple drug candidates with differing and complementary mechanisms of action targeting HBV. These include AB-506, the Company's oral capsid inhibitor currently in a Phase 1a/1b clinical trial, AB-729, the Company's second generation RNA interface ("RNAi") therapeutic candidate, and AB-452, the Company's lead oral RNA destabilizer candidate. </font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The success of the Company is dependent on obtaining the necessary regulatory approvals to bring its products to market and achieving profitable operations. The Company's research and development activities and commercialization of its products are dependent on its ability to successfully complete these activities and to obtain adequate financing through a combination of financing activities and operations. It is not possible to predict either the outcome of the Company's existing or future research and development programs or the Company’s ability to continue to fund these programs in the future.</font></div></div>

Files In Submission

Name	View Source	Status
0001447028-19-000015-index-headers.html	Edgar Link	pending
0001447028-19-000015-index.html	Edgar Link	pending
0001447028-19-000015.txt	Edgar Link	pending
0001447028-19-000015-xbrl.zip	Edgar Link	pending
abus-20190331.xml	Edgar Link	completed
abus-20190331.xsd	Edgar Link	pending
abus-20190331_cal.xml	Edgar Link	unprocessable
abus-20190331_def.xml	Edgar Link	unprocessable
abus-20190331_lab.xml	Edgar Link	unprocessable
abus-20190331_pre.xml	Edgar Link	unprocessable
arbutusq12019.htm	Edgar Link	pending
exhibit101koertvandenenden.htm	Edgar Link	pending
exhibit311q12019.htm	Edgar Link	pending
exhibit312q12019.htm	Edgar Link	pending
exhibit321q12019.htm	Edgar Link	pending
exhibit322q12019.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
hbvpipelinenoexplanatorytext.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ABUS
Arbutus Biopharma Corp Stock $abus

2019 Q1 Form 10-Q Financial Statement

#000144702819000015 Filed on May 06, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABUS Arbutus Biopharma Corp Stock $abus

2019 Q1 Form 10-Q Financial Statement

#000144702819000015 Filed on May 06, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ABUS
Arbutus Biopharma Corp Stock $abus